Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota

Rashid, Mamun Ur; Rosenborg, Staffan; Panagiotidis, Georgios; Söderberg-Löfdal, Karin; Weintraub, Andrej; Nord, Carl Erik

doi:10.1128/aac.00530-15

Cited by 13 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results also showed that Bacteroides abundance was not significantly altered by cephalosporin. It supports previous findings investigating the effect of cephalosporins on the intestinal microbiota (Burdet et al 2019;Rashid et al 2015). Apart from a decrease in the abundance of several genera, there was an increase in Christensenella, Rothia, Abiotrophia, Acinetobacter, Anaerotruncus, Holdemania, and Turicibacter.…”

Section: Discussionsupporting

confidence: 91%

Effect of mare’s milk prebiotic supplementation on the gut microbiome and the immune system following antibiotic therapy

et al. 2020

View full text Add to dashboard Cite

Abstract. Nurgaziyev M, Atenov Y, Khassenbekova Z, Akpanova S, Rysbekov K, Kozhakhmetov S, Nurgozhina A, Sergazy S, Chulenbayeva L, Ospanova Z, Tuyakova A, Mukhambetganov N, Sattybayeva R, Urazova S, Galymgozhina N, Zhumadilova A, Gulyaev A, Kushugulova A. 2020. Effect of mare’s milk prebiotic supplementation on the gut microbiome and the immune system following antibiotic therapy. Biodiversitas 21: 5065-5071. Antibiotic treatment can severely affect the gut microbiome for short-term and long-term consequences. Probiotic and prebiotic supplements are widely prescribed to modulate the composition and function of the human gut microbiome. The current study aims to determine the impacts of mare’s milk prebiotics on the diversity of gut bacterial communities and the local immune system when administered during and after a course of antibiotic therapy. Six children aged 4 to 5 years diagnosed with bilateral bronchopneumonia were prescribed cephalosporin (cefuroxime) antibiotics. During the 60 days of the study, three children consumed mare’s milk prebiotics, while the other three did not. Fecal samples were collected daily during antibiotic therapy and every five days after the last day of antibiotic treatment. Total DNA was isolated, and the taxonomic composition of the gut microbiome was analyzed by sequencing the 16S rRNA gene (V1-V3 region). The MULTIPLEX MAP platform was used to evaluate the local immune status. The relative abundance of 11 genera was reduced and did not recover until the last day of the study. The abundance of Bacteroides was not significantly altered in either group. Christensenella, Rothia, Abiotrophia, Acinetobacter, Anaerotruncus, Holdemania, and Turicibacter numbers were significantly increased on day five and remained at the same level during the study period. Cephalosporin administration also reduced the levels of pro-inflammatory and anti-inflammatory cytokines/chemokines (MIP1α, TNFα, GMCSF, GCSF, sCD40L, FGF2, TGFα, IL1α, and IP10).

show abstract

Section: Discussionsupporting

confidence: 91%

Effect of mare’s milk prebiotic supplementation on the gut microbiome and the immune system following antibiotic therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A toxigenic C. difficile strain was reported in one patient, but this was not associated with adverse events. 57 …”

Section: Are All Cephalosporins the Same With Regard To CDI Risk?mentioning

confidence: 99%

Role of cephalosporins in the era ofClostridium difficileinfection

Wilcox

Chalmers

Nord

et al. 2016

J. Antimicrob. Chemother.

View full text Add to dashboard Cite

The incidence of Clostridium difficile infection (CDI) in Europe has increased markedly since 2000. Previous meta-analyses have suggested a strong association between cephalosporin use and CDI, and many national programmes on CDI control have focused on reducing cephalosporin usage. Despite reductions in cephalosporin use, however, rates of CDI have continued to rise. This review examines the potential association of CDI with cephalosporins, and considers other factors that influence CDI risk. EUCLID (the EUropean, multicentre, prospective biannual point prevalence study of CLostridium difficile Infection in hospitalized patients with Diarrhoea) reported an increase in the annual incidence of CDI from 6.6 to 7.3 cases per 10 000 patient bed-days from 2011–12 to 2012–13, respectively. While CDI incidence and cephalosporin usage varied widely across countries studied, there was no clear association between overall cephalosporin prescribing (or the use of any particular cephalosporin) and CDI incidence. Moreover, variations in the pharmacokinetic and pharmacodynamic properties of cephalosporins of the same generation make categorization by generation insufficient for predicting impact on gut microbiota. A multitude of additional factors can affect the risk of CDI. Antibiotic choice is an important consideration; however, CDI risk is associated with a range of antibiotic classes. Prescription of multiple antibiotics and a long duration of treatment are key risk factors for CDI, and risk also differs across patient populations. We propose that all of these are factors that should be taken into account when selecting an antibiotic, rather than focusing on the exclusion of individual drug classes.

show abstract

“…While this has been demonstrated using murine models (81), monitoring human C. albicans intestinal colonization levels is more problematic. However, more recent clinical studies examining fecal loads have demonstrated increased Candida levels with antibotic treatment (101). Overgrowth may facilitate localized mucosal infection and/or generalized GI tract disturbances, but the validity of GI candidiasis via overgrowth as a clinical entity is controversial (102,103).…”

Section: Non-cd4mentioning

confidence: 99%

Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework

et al. 2016

View full text Add to dashboard Cite

f Historically, the nature and extent of host damage by a microbe were considered highly dependent on virulence attributes of the microbe. However, it has become clear that disease is a complex outcome which can arise because of pathogen-mediated damage, host-mediated damage, or both, with active participation from the host microbiota. This awareness led to the formulation of the damage response framework (DRF), a revolutionary concept that defined microbial virulence as a function of host immunity. The DRF outlines six classifications of host damage outcomes based on the microbe and the strength of the immune response. In this review, we revisit this concept from the perspective of Candida albicans, a microbial pathogen uniquely adapted to its human host. This fungus commonly colonizes various anatomical sites without causing notable damage. However, depending on environmental conditions, a diverse array of diseases may occur, ranging from mucosal to invasive systemic infections resulting in microbe-mediated and/or host-mediated damage. Remarkably, C. albicans infections can fit into all six DRF classifications, depending on the anatomical site and associated host immune response. Here, we highlight some of these diverse and site-specific diseases and how they fit the DRF classifications, and we describe the animal models available to uncover pathogenic mechanisms and related host immune responses.

show abstract

Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota

Cited by 13 publications

References 19 publications

Effect of mare’s milk prebiotic supplementation on the gut microbiome and the immune system following antibiotic therapy

Effect of mare’s milk prebiotic supplementation on the gut microbiome and the immune system following antibiotic therapy

Role of cephalosporins in the era ofClostridium difficileinfection

Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework

Contact Info

Product

Resources

About